Menu Search
Equities

GT Biopharma Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
OXIA:MUN

GT Biopharma Inc

Actions
  • Price (EUR)0.545
  • Today's Change0.00 / 0.00%
  • Shares traded5.00k
  • 1 Year change--
  • Beta1.2671
Data delayed at least 15 minutes, as of Dec 10 2025 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

  • Revenue in USD (TTM)0.00
  • Net income in USD-9.33m
  • Incorporated1973
  • Employees1.00
  • Location
    GT Biopharma Inc505 MONTGOMERY STREET, 10TH FLOORSAN FRANCISCO 94111United StatesUSA
  • Phone+1 (310) 551-4020
  • Fax+1 (302) 655-5049
  • Websitehttps://www.gtbiopharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.